AYTU BIOPHARMA INC (AYTU)
US0547548588 - Common Stock
| MRQ (2023-12-31) | 2023 (2023-6-30) | 2022 (2022-6-30) | 2021 (2021-6-30) | 2020 (2020-6-30) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | N/A | N/A | N/A | N/A | N/A | |||
| Cash Equivalents | 19.53M | 23.00M | 19.40M | 49.60M | 48.10M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | N/A | |||
| Receivables | 29.40M | 28.90M | 21.70M | 28.20M | 5.60M | |||
| Inventories | 13.00M | 12.00M | 10.80M | 16.30M | 10.00M | |||
| Other Current Assets | 9.44M | 8.90M | 8.00M | 11.10M | 11.70M | |||
| Total Current Assets | 71.37M | 72.80M | 59.90M | 105.20M | 75.40M | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.26M | 3.90M | 6.30M | 8.70M | 900.00K | |||
| Goodwill | N/A | N/A | 0.00 | 65.80M | 28.10M | |||
| Intangibles | 55.71M | 59.00M | 70.60M | 85.50M | 48.90M | |||
| Other Non-Current Assets | 907.00K | 800.00K | 800.00K | 500.00K | 0.00 | |||
| Total Non-Current Assets | 59.88M | 63.70M | 77.70M | 160.50M | 77.90M | |||
| TOTAL ASSETS | 131.25M | 136.50M | 137.60M | 265.70M | 153.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 1.03M | 1.60M | 3.80M | 7.90M | 0.00 | |||
| Current Portion Of LT Debt. | 39.00K | 100.00K | 100.00K | 16.70M | 0.00 | |||
| Accrued Expenses | 32.94M | 37.00M | 35.90M | 49.50M | 11.10M | |||
| Accounts Payable | 22.31M | 24.50M | 20.50M | 28.00M | 12.80M | |||
| Other Current Liabilities | 7.87M | 5.80M | 4.10M | 7.40M | 4.90M | |||
| Total Current Liabilities | 64.19M | 69.00M | 64.40M | 109.40M | 28.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 14.98M | 14.70M | 14.30M | 200.00K | 0.00 | |||
| Other Non-Current Liabilities | 19.23M | 13.40M | 12.80M | 18.50M | 29.50M | |||
| Total Non-Current Liabilities | 34.21M | 28.10M | 27.10M | 18.70M | 29.50M | |||
| TOTAL LIABILITIES | 98.40M | 97.10M | 91.50M | 128.10M | 58.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -312.47M | -304.10M | -288.50M | -178.30M | -120.00M | |||
| Additional Paid In Capital | 345.32M | 343.50M | 334.60M | 315.90M | 215.00M | |||
| Common Shares | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 5.57M | 5.50M | 1.90M | 1.40M | 600.00K | |||
| Tangible Book Value per Share | -4.11 | -3.56 | -12.89 | -9.79 | 30.00 | |||
| Total Shareholders' Equity | 32.85M | 39.40M | 46.10M | 137.60M | 95.00M | |||
| TOTAL LIABILITIES AND EQUITY | 131.25M | 136.50M | 137.60M | 265.70M | 153.30M | |||
| Statistics | ||||||||
| Debt/Equity | 0.49 | 0.41 | 0.39 | 0.06 | N/A | |||
| Current Ratio | 1.11 | 1.06 | 0.93 | 0.96 | 2.62 | |||
| Return On Assets (ROA) | -13.71% | -12.53% | -79.07% | -21.94% | -8.87% | |||
| Return On Equity (ROE) | -54.79% | -43.40% | -236.01% | -42.37% | -14.32% | |||
All data in USD